Trial Profile
A Prospective, observational real life study on the safety of the Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + Ribavirin regimen in patients with Compensated HCV Cirrhosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2016
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C; Liver cirrhosis
- Focus Adverse reactions
- 12 Dec 2016 New trial record
- 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week